share_log

D. Boral Capital Initiates Coverage On Context Therapeutics With Buy Rating, Announces Price Target of $9

Benzinga ·  Nov 25 07:53  · Ratings

D. Boral Capital analyst Jason Kolbert initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment